Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
1.
J Infect Chemother ; 28(2): 329-332, 2022 Feb.
Article in English | MEDLINE | ID: covidwho-1531583

ABSTRACT

Lymphoma has been reported to worsen the prognosis of COVID-19 partly because it disturbs the normal production of antibodies. We treated a man with mantle cell lymphoma treated with rituximab, who developed severe COVID-19 with viral shedding that lasted for 78 days. He stayed in the intensive care unit for 28 days and did not respond to any treatment against COVID-19. His increased oxygen demand at rest eventually resolved despite the absence of anti-SARS-CoV-2-IgG. This case illustrates that recovery from COVID-19 can occur without antibody production, and that even patients with an inability to produce antibodies can recover from severe COVID-19. It also illustrates that lymphoma patients who develop severe COVID-19 while on rituximab therapy can recover from a prolonged viral shedding state if the acute lung injury can be overcome.


Subject(s)
COVID-19 , Lymphoma, Mantle-Cell , Adult , Antibodies, Viral , Antibody Formation , Humans , Lymphoma, Mantle-Cell/drug therapy , Male , Rituximab/therapeutic use , SARS-CoV-2
3.
Eur J Immunol ; 51(10): 2478-2484, 2021 10.
Article in English | MEDLINE | ID: covidwho-1340251

ABSTRACT

Treatment with convalescent plasma has been shown to be safe in coronavirus disease in 2019 (COVID-19) infection, although efficacy reported in immunocompetent patients varies. Nevertheless, neutralizing antibodies are a key requisite in the fight against viral infections. Patients depleted of antibody-producing B cells, such as those treated with rituximab (anti-CD20) for hematological malignancies, lack a fundamental part of their adaptive immunity. Treatment with convalescent plasma appears to be of general benefit in this particularly vulnerable cohort. We analyzed clinical course and inflammation markers of three B-cell-depleted patients suffering from COVID-19 who were treated with convalescent plasma. In addition, we measured serum antibody levels as well as peripheral blood CD38/HLA-DR-positive T-cells ex vivo and CD137-positive T-cells after in vitro stimulation with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-derived peptides in these patients. We observed that therapy with convalescent plasma was effective in all three patients and analysis of CD137-positive T-cells after stimulation with SARS-CoV-2 peptides showed an increase in peptide-specific T-cells after application of convalescent plasma. In conclusion, we here demonstrate efficacy of convalescent plasma therapy in three B-cell-depleted patients and present data that suggest that while application of convalescent plasma elevates systemic antibody levels only transiently, it may also boost specific T-cell responses.


Subject(s)
Antibodies, Viral/blood , B-Lymphocytes/immunology , COVID-19/therapy , T-Lymphocytes/immunology , Adolescent , Aged , Antibodies, Neutralizing/blood , B-Lymphocytes/cytology , Humans , Immunity, Cellular/immunology , Immunization, Passive/methods , Lymphocyte Count , Lymphocyte Depletion , Lymphoma, B-Cell/drug therapy , Lymphoma, Mantle-Cell/drug therapy , Male , Middle Aged , Precursor Cell Lymphoblastic Leukemia-Lymphoma/drug therapy , Rituximab/adverse effects , SARS-CoV-2/immunology , Treatment Outcome , Tumor Necrosis Factor Receptor Superfamily, Member 9/metabolism
6.
Am J Trop Med Hyg ; 103(5): 1983-1985, 2020 11.
Article in English | MEDLINE | ID: covidwho-771325

ABSTRACT

COVID-19 has now spread globally, and 10-20% of the cases are thought to proceed to a severe condition. However, information on COVID-19 in immunodeficient patients remains limited. We treated a 56-year-old man who developed COVID-19 after chemotherapy for mantle cell lymphoma. After 1 month of prolonged fever, the patient's respiratory condition deteriorated rapidly, and he died. COVID-19 in immunocompromised patients after chemotherapy, even with mild symptoms, can cause rapid immune reconstitution and respiratory deterioration. Therefore, caution is advised until negative PCR test results for SARS-CoV-2 are confirmed.


Subject(s)
Bone Marrow Failure Disorders/chemically induced , COVID-19/etiology , Cross Infection/chemically induced , Lymphoma, Mantle-Cell/drug therapy , SARS-CoV-2/isolation & purification , Bone Marrow Failure Disorders/complications , COVID-19/diagnostic imaging , COVID-19/drug therapy , Cross Infection/complications , Cross Infection/etiology , Humans , Immunocompromised Host , Lymphoma, Mantle-Cell/complications , Lymphoma, Mantle-Cell/immunology , Male , Middle Aged , Pharynx/virology , Polymerase Chain Reaction , Radiography, Thoracic , SARS-CoV-2/genetics , Tomography, X-Ray Computed
7.
Br J Haematol ; 190(2): 185-188, 2020 07.
Article in English | MEDLINE | ID: covidwho-626838

ABSTRACT

SARS-CoV-2 infection can cause severe pneumonia (COVID-19). There is evidence that patients with comorbidities are at higher risk of a severe disease course. The role of immunosuppression in the disease course is not clear. In the present report, we first describe two cases of persisting SARS-CoV-2 viraemia with fatal outcome in patients after rituximab therapy.


Subject(s)
Coronavirus Infections/pathology , Pneumonia, Viral/pathology , Rituximab/administration & dosage , Viremia/diagnosis , Aged , B-Lymphocytes/pathology , Betacoronavirus , COVID-19 , Coronavirus Infections/complications , Fatal Outcome , Humans , Immunocompromised Host , Lymphoma, Large B-Cell, Diffuse/complications , Lymphoma, Large B-Cell, Diffuse/drug therapy , Lymphoma, Mantle-Cell/complications , Lymphoma, Mantle-Cell/drug therapy , Male , Middle Aged , Pandemics , Pneumonia, Viral/complications , SARS-CoV-2
SELECTION OF CITATIONS
SEARCH DETAIL